INTRODUCTION AND OBJECTIVES: Leucine stimulates cancer cell proliferation through the mTOR pathway, therefore, inhibiting leucine transporters can be a novel therapeutic strategy. One of leucine transporters, L-type amino acid transporter (LAT) 1 (SLC7A5), a Na + -independent amino acid transporter, has been reported to be selectively expressed in many cancer cells. Recently it has been shown that primary prostate cancer expresses LAT3 (SLC43A1), while castration resistant or highly aggressive prostate cancer expresses LAT1 as a main leucine transporter. In this study, we examine leucine transporters during acquisition of hormone independence.
METHODS: A new 00 LN-abl 00 cell line was established after culturing LNCaP cells for 6 months under androgen-free conditions, which is a model of castration resistant prostate cancer (CRPC) with androgen receptor expression. Uptake of 14 C leucine was examined in the presence or absence of LAT inhibitors or Na + . Expression of a major leucine transporter was inhibited by siRNA in LN-abl cells. In silico analysis of leucine transporter expression was examined using Oncomine for different progression status of prostate cancers in clinical data sets. RESULTS: Cell viability was decreased to 10% in the absence of leucine. LNCaP cells principally expressed LAT3, and their leucine uptake was more than 90% Na + -independent. In LN-abl cells, Na +dependent uptake of leucine was 3.8 pmol/mgprotein/min, while, Na +independent uptake was only 0.52, therefore, leucine uptake of LN-abl was largely (~85%) Na + -dependent. y + LAT2 (SLC7A6) expression was confirmed in LN-abl, however, expression of LAT1, LAT3, y + LAT1 (SLC7A7), ATB0 + (SLC6A14), B0AT1 (SLC6A19), B0AT2 (SLC6A15) or b0 + AT (SLC7A9) were not observed. Knockdown of y + LAT2 lead to significant leucine uptake inhibition (40%) and cell growth inhibition (20%) in LN-abl cells. In silico analysis revealed that more frequent upregulation of SLC7A6 (y + LAT2) was observed in hormone resistant or metastatic samples in 2 data sets. In addition, some advanced prostate cancer appeared to express high levels of LAT3, suggesting heterogeneity in leucine transporter expression among different prostate cancers.
CONCLUSIONS: New CRPC cell line with increased expression of y + LAT2 was established in vitro. This is consistent with the fact that at least some advanced stage prostate cancers express y + LAT2 in Oncomine data. Considering the diversity of leucine transporter expression, target of anti-leucine transporter therapy should be individualized.
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TISSUE-SPECIFIC RADIATION SENSITIZATION OF PROSTATE CANCER BY APTAMER TARGETED SIRNA KNOCK-DOWN OF DNA REPAIR PATHWAY Kenji Zennami*, Yonggang Zhang, Haoming Zhou, Daniel Thorek, Theodore DeWeese, Shawn Lupold, Baltimore, MD INTRODUCTION AND OBJECTIVES: Radiosensitizing agents can improve ionizing radiation (IR) potency. We have previously reported that an A10-3-DNAPK chimera can deliver radiation-sensitizing short interfering RNA (anti-DNA-PK siRNA) to prostate cancer cells and subcutaneous tumors through the PSMA-targeting RNA aptamer, A10-3. Here we describe the DNA-PK knock-down and radiation-sensitizing effect of the A10-3-DNAPK chimera on a human prostate cancer xenograft model in the mouse tibia, and its evaluation by bioluminescent imaging, immunohistochemistry and micro-CT.
METHODS: Five to six-week-old male athymic nude mice were anesthetized by isoflurane, then luciferase expressing human prostate cancer cells (LNCaP-luc) were inoculated into tibias. Tumors were evaluated by IVIS bioluminescent imaging 6 weeks after implantation, then IVIS positive mice were separated into three groups and treated by PBS, A103-ctrl and A103-DNAPK via tail vein injection. For the confirmation of DNAPK knock-down, tibias were harvested 72hrs post injection and evaluated by HE staining and immunohistochemistry. In order to confirm radiation-sensitizing effect, half of the tumors received IR therapy (6 Gy) directly to the tumored leg. Four weeks after IR, the tibias were harvested and tumor burden assessed ex vivo by nanoScan PET/CT and VivoQuant software. The CT value (HU) from these images were applied to automatically assign regions of interest for bone (red, HU 5,000-10,000) and marrow (green, HU <5,000) ( Fig 1B) . The sum HU were then calculated for each treatment group to estimate tumor burden four weeks after treatment.
RESULTS: Immunohistochemistry demonstrated reduction of DNAPK protein after A103-DNAPK treatment (Fig 1A: 50% , 38% less than PBS, A103-ctrl, respectively). The results of CT indicate significantly reduced tumor volume in A103-DNAPK pre-treated animals, with IR, when compared to animals pre-treated with PBS or A103-Ctrl ( Fig  1C: p ¼0.045 and p¼0.026, respectively).
CONCLUSIONS: Systemically injected aptamer siDNAPK can induce PSMA specific radiosensitization through DNAPK knock-down in human prostate tumor within mouse tibia. This system could be used to enhance radiation therapy of locally advanced PCa. . 197, No. 4S, Supplement, Monday, May 15, 2017 
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